FindTrial
Sign In

Amelioration of glucose homeostasis and visceral adiposity in metabolic syndrome by mild electrical current and thermo therapy

Amelioration of glucose homeostasis and visceral adiposity in metabolic syndrome by mild electrical current and thermo therapy - Metabolic ameliorations in metabolic syndrome by MET

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001149
Enrollment
80
Registered
2008-06-01
Start date
2008-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic syndrome

Interventions

12 weeks of MET (4 times a week, 60 min each time), and then 12 weeks of withdrawal, 40 subjects. 12 weeks of no treatment, and then 12 weeks of MET (4 times a week, 60 min each time), 40 subjects.

Sponsors

Department of Metabolic Medicine, Graduate School of Medical Sciences, Kumamoto University
Lead Sponsor
Japanese Red Cross Society, Kumamoto Health Care Center.
Collaborator

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Abdominal obesity, given as waist circumference greater than 85 cm with meets 2 criteria in 3 shown below, i)Triglycerides: greater than or equal to 150 mg/dL and/or HDL cholesterol: less than 40 mg/dL ii)Systolic Blood pressure: greater than or equal to130 mmHg and/or Diastolic blood pressure: greater than or equal to 85 mmHg iii)Fasting blood glucose: greater than or equal to 110 mg/dL

Exclusion criteria

Exclusion criteria: i) Past history or current medication of myocardial infarction, angina, apoplexy and arteriosclerosis obliterans. ii)Severe wound, infections, pre- or post-operation. iii)Severe liver dysfunction (GOT and/or GPT: greater than 100U). iv)Chronic heart failure, familial dyslipidemia. v)Severe diabetic complications. vi)HbA1c : greater than or equal to 6.5%. vii)Pacemaker carrier.

Design outcomes

Primary

MeasureTime frame
Changes of biomarkers related to metabolic syndrome at 12 weeks and 24 weeks after MET treatment.—

Secondary

MeasureTime frame
General assessment of MET device evaluated by subjects.—

Countries

Japan

Contacts

Public ContactTatsuya Kondo

Graduate School of Medical Sciences, Department of Metabolic Medicine

t-kondo@gpo.kumamoto-u.ac.jp096-373-5169

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026